Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer

News provided by

Feb 21, 2023, 08:00 ET

SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Shoreline Biosciences, Inc. (Shoreline), a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms, today announced the appointment of Mauro P. Avanzi, M.D., Ph.D. as Chief Medical Officer.

Shoreline Biosciences Announces Appointment of Mauro P. Avanzi, M.D., Ph.D., As Chief Medical Officer

Dr. Avanzi is an experienced physician-scientist and hematologist/oncologist with over fifteen years of clinical experience, including over ten years of experience advancing cellular therapies through early and late-stage of development. In his new role, Dr. Avanzi will be responsible for leading and expanding Shoreline's clinical portfolio and will serve as a key member of its Executive team.

"We are extremely pleased that Mauro is joining Shoreline at such a pivotal time in the growth of our company. Mauro is a recognized immuno-oncology expert with a wealth of expertise in leading cross-functional clinical teams that have advanced important cellular therapies through all stages of development, including commercial approval in global markets," said Kleanthis G. Xanthopoulos, Ph.D., Shoreline's Chairman and CEO. "Mauro's unique background and proven track record in cell therapy will strengthen our capabilities as we bring next-generation immunotherapies to patients with cancer."

Prior to joining Shoreline, Dr. Avanzi served as Vice President, Clinical Development at Neogene Therapeutics (acquired by AstraZeneca), where he was responsible for leading clinical studies with TCR T cells targeting neoantigens. Prior to Neogene, Dr. Avanzi held a number of positions of increasing responsibility at Kite Pharma (acquired by Gilead), where he supported multiple clinical programs through all stages of development. Dr. Avanzi has extensive clinical development experience in both the US and EU, and has played an integral role in multipe IND/CTA and sBLA filings, including the commercial approval of Yescarta for indolent NHL. Dr. Avanzi earned his M.D. at Campinas Medical School (Puc) in Brazil and completed an internal medicine residency and hematology/oncology fellowship at the São Paulo University (USP). He completed his Ph.D. research at the New York Blood Center/Santa Casa Medical School and a post-doctoral fellowship focusing on CAR-T cells at Memorial Sloan Kettering Cancer Center. Dr. Avanzi is an author of multiple peer-reviewed publications on adoptive cellular therapies.

Dr. Avanzi commented, "I have long admired Shoreline's focus and leadership position in cell therapy and I am very excited about the clinical potential of the Shoreline pipeline. I believe that Shoreline has the strongest set of tools to win the war on cancer, including its industry-leading iPSC derived iNK and iMAC platforms and the recent addition of key gene-editing and manufacturing technologies. The company's deep expertise in iPSC differentiation, immune cell biology, and gene-editing make this an opportunity that I find very compelling, and I look forward to building a meaningful clinical portfolio that will deliver therapeutic benefit to patients."

About Shoreline Biosciences

Shoreline Biosciences is a biopharmaceutical company developing next-generation cellular immunotherapies based on induced pluripotent stem cells (iPSCs) utilizing its proprietary iPSC-derived natural killer (iNK) cell and macrophage (iMACs) platforms. The company's cellular design technologies are built on a deep understanding of iPSC differentiation, immune cell biology and genetic engineering that enable the development of specific effector cell types, including iNK cells and iMACs as allogeneic "off-the-shelf" cellular immunotherapies designed for durability, scalability, safety, and efficacy. Shoreline is advancing a pipeline of programs towards the clinic, on its own and with its strategic partners, Kite, a Gilead Company, and BeiGene, a global pharmaceutical company. Shoreline Biosciences is headquartered in San Diego, CA.

For more information, please visit https://shorelinebio.com/ and engage with us on LinkedIn.

Investor Contact:
Amy Conrad
Juniper Point
[email protected]
858-366-3243

Media Contact:
David Schull
Russo Partners
[email protected]
212-845-4271

SOURCE Shoreline Biosciences, Inc.